CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Regulation FD Disclosure
Item7.01
| Other Events. |
Attached hereto as Exhibit 99.1 is a PowerPoint presentation that
Cempra, Inc. will use for presentations to investors and
healthcare conferences, and which is incorporated herein by
reference.
The information in this Item7.01 (including Exhibit 99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item9.01. |
Financial Statements and Exhibits. |
(d) |
Exhibits |
|
|
|
|
| 99.1 | Corporate Presentation of January 2017. |
About CEMPRA, INC. (NASDAQ:CEMP)
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI). CEMPRA, INC. (NASDAQ:CEMP) Recent Trading Information
CEMPRA, INC. (NASDAQ:CEMP) closed its last trading session down -0.28 at 3.47 with 4,891,089 shares trading hands.